GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (STU:CXF) » Definitions » Common Stock

Chimerix (STU:CXF) Common Stock : €0.08 Mil (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Chimerix Common Stock?

Chimerix's quarterly common stock declined from Sep. 2023 (€0.08 Mil) to Dec. 2023 (€0.08 Mil) but then increased from Dec. 2023 (€0.08 Mil) to Mar. 2024 (€0.08 Mil).

Chimerix's annual common stock increased from Dec. 2021 (€0.08 Mil) to Dec. 2022 (€0.08 Mil) but then declined from Dec. 2022 (€0.08 Mil) to Dec. 2023 (€0.08 Mil).


Chimerix Common Stock Historical Data

The historical data trend for Chimerix's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix Common Stock Chart

Chimerix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.05 0.08 0.08 0.08

Chimerix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.08 0.08 0.08

Chimerix Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Chimerix (STU:CXF) Business Description

Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.

Chimerix (STU:CXF) Headlines

No Headlines